ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1591

Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)

Marco Garrido-Cumbrera1, Helena Marzo-Ortega2, Laura Christen3, José Correa-Fernández4, Sergio Sanz-Gomez4, Pedro Plazuelo-Ramos5, Laurent Grange6, Dale Webb7, Shantel Irwin8, Clare Jacklin9, Souzi Makri10, Elsa Frazão Mateus11, Serena Mingolla12, Katy Antonopoulou13 and Victoria Navarro-Compán14, 1Health & Territory Research (HTR), University of Seville, Sevilla, Spain, 2NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, 3Novartis Pharma AG, Basel, Switzerland, 4Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, 5Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, 6French League Against Rheumatism (AFLAR), Echirolles, France, 7National Axial Spondyloarthritis Society (NASS), London, United Kingdom, 8Arthritis Action, London, United Kingdom, 9National Rheumatoid Arthritis Society (NRAS), London, United Kingdom, 10Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, 11Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 12Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Bari, Italy, 13Hellenic League Againts Rheumatism (ELEANA), Athens, Greece, 14Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain

Meeting: ACR Convergence 2021

Keywords: COVID-19, Patient reported outcomes, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in European RMD patients.

Methods: REUMAVID is an international collaboration led by the Health & Territory Research group at the University of Seville, together with a multidisciplinary team including patient organisations and rheumatologists. The study consists of an online survey gathering data from patients with a diagnosis of 15 RMDs in Cyprus, France, Greece, Italy, Portugal, Spain, and the United Kingdom. 1,800 participants were recruited by patient organisations. Data was collected between April and July 2020. Participants were divided into two groups: 1) Participants with poor wellbeing (World Health Organization-Five Wellbeing Index (WHO-5) ≤ 50), 2) Participants with good wellbeing (WHO-5 >50). The Mann-Whitney and χ2 tests were used to analyse possible relations between sociodemographic characteristics, lifestyle, and outdoor contact with wellbeing during the beginning of the COVID-19 pandemic. Univariate and multivariate binary logistic regression was used to determine the impact of the independent variables associated with poor wellbeing.

Results: 1,777 patients with 15 different RMDs were included. The mean age was 52.7, 80.2% female, 48.7% had a university degree, and 69.7% were married or in a relationship. The most frequent diagnoses were inflammatory arthritis (75.4%). 49.0% reported poor wellbeing. 57.7% of patients who belonged to a patient organisation reported good wellbeing (vs 46.3% who did not, p< 0.001). Compared to those patients who did not, those who did experienced poor wellbeing had higher disease activity (51.4% vs 41.3%, p< 0.001), a higher risk of anxiety (54.3% vs 41.7%, p< 0.001) and depression (57.0% vs 42.1%, p< 0.001), and poorer self-perceived health (53.0% vs 41.8%, p< 0.001). A higher proportion of those who engaged in physical activity presented good wellbeing (54.0% vs 46.5%, p=0.012). 57.4% of the patients who were unable to attend an appointment with their rheumatologist reported poor wellbeing, compared to 48.2% who did attend (p=0.027). Patients who did not walk outside (56.2%) or who lacked elements in their home to facilitate outside contact (63.3%) experienced poor wellbeing (p< 0.001). The factors associated with poor wellbeing were lack of elements in the home enabling contact with the outside world (OR=2.10), not belonging to a patient organisation (OR=1.51), risk of depression (OR=1.49), and not walking outside (OR=1.36) during the COVID-19 pandemic (Table 1).

Conclusion: Almost half of the patients with RMDs reported poor wellbeing during the beginning of the COVID-19 pandemic. The lack of elements in the home that facilitate outdoor contact, not belonging to a patient organisation, the presence of anxiety, and not walking outside during the pandemic increase the probability of poor well-being. These results highlight the importance of environmental factors and the role of patient organisations in addressing the effects of the pandemic and its containment measures.

Table 1. Logistic regression. Dependent variable: poor wellbeing (N&#3f1,104)


Disclosures: M. Garrido-Cumbrera, None; H. Marzo-Ortega, Janssen, 2, 5, 6, Takeda, 6, Novartis, 2, 5, 6, UCB, 2, 5, 6, Celgene, 2, 6, AbbVie, 2, 6, Lilly, 2, 6, Pfizer, 2, 6; L. Christen, Novartis, 3; J. Correa-Fernández, None; S. Sanz-Gomez, None; P. Plazuelo-Ramos, None; L. Grange, None; D. Webb, AbbVie, 5, Biogen, 5, Janssen, 5, Lilly, 5, Novartis, 5, UCB, 5; S. Irwin, The National Lottery Community Fund, 12, Coronavirus Community Support Fund; C. Jacklin, Abbvie, 5, Amgen, 5, Biogen, 5, Eli Lilly, 5, Gilead, 5, Janssen, 5, Pfizer, 5, Roche, 5, Sanofi, 5, UCB, 5; S. Makri, None; E. Frazão Mateus, Boehringer Ingelheim, 6, Pfizer, 5, 12, Non-financial, Lilly Portugal, 5, Sanofi, 5, AbbVie, 5, Novartis, 5, Grünenthal. SA., 5, MSD, 5, Celgene, 5, Medac, 5, Janssen-Cilag, 5, Pharmakern, 5, GAfPA, 5; S. Mingolla, None; K. Antonopoulou, None; V. Navarro-Compán, Abbvie, 5, Lilly, 5, Novartis, 5, Pfizer, 5, UCB, 5, Janssen, 5.

To cite this abstract in AMA style:

Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Correa-Fernández J, Sanz-Gomez S, Plazuelo-Ramos P, Grange L, Webb D, Irwin S, Jacklin C, Makri S, Frazão Mateus E, Mingolla S, Antonopoulou K, Navarro-Compán V. Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impact-of-the-covid-19-pandemic-and-lockdown-on-wellbeing-on-patients-with-rheumatic-diseases-results-from-the-reumavid-study-phase-1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-the-covid-19-pandemic-and-lockdown-on-wellbeing-on-patients-with-rheumatic-diseases-results-from-the-reumavid-study-phase-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology